...
首页> 外文期刊>Cell death & disease. >MicroRNA-27a-5p regulation by promoter methylation and MYC signaling in prostate carcinogenesis
【24h】

MicroRNA-27a-5p regulation by promoter methylation and MYC signaling in prostate carcinogenesis

机译:MicroRNA-27a-5p通过启动子甲基化和MYC信号调节前列腺癌的发生

获取原文
           

摘要

Upregulation of MYC and miRNAs deregulation are common in prostate cancer (PCa). Overactive MYC may cause miRNAs’ expression deregulation through transcriptional and post-transcriptional mechanisms and epigenetic alterations are also involved in miRNAs dysregulation. Herein, we aimed to elucidate the role of regulatory network between MYC and miRNAs in prostate carcinogenesis. MYC expression was found upregulated in PCa cases and matched precursor lesions. MicroRNA’s microarray analysis of PCa samples with opposed MYC levels identified miRNAs significantly overexpressed in high-MYC PCa. However, validation of miR-27a-5p in primary prostate tissues disclosed downregulation in PCa, instead, correlating with aberrant promoter methylation. In a series of castration-resistant PCa (CRPC) cases, miR-27a-5p was upregulated, along with promoter hypomethylation. MYC and miR-27a-5p expression levels in LNCaP and PC3 cells mirrored those observed in hormone-naíve PCa and CRPC, respectively. ChIP analysis showed that miR-27a-5p expression is only regulated by c-Myc in the absence of aberrant promoter methylation. MiR-27a-5p knockdown in PC3 cells promoted cell growth, whereas miRNA forced expression in LNCaP and stable MYC-knockdown PC3 cells attenuated the malignant phenotype, suggesting a tumor suppressive role for miR-27a-5p. Furthermore, miR-27a-5p upregulation decreased EGFR/Akt1/mTOR signaling. We concluded that miR-27a-5p is positively regulated by MYC, and its silencing due to aberrant promoter methylation occurs early in prostate carcinogenesis, concomitantly with loss of MYC regulatory activity. Our results further suggest that along PCa progression, miR-27a-5p promoter becomes hypomethylated, allowing for MYC to resume its regulatory activity. However, the altered cellular context averts miR-27a-5p from successfully accomplishing its tumor suppressive function at this stage of disease.
机译:MYC的上调和miRNA的下调在前列腺癌(PCa)中很常见。 MYC过度活跃可能通过转录和转录后机制导致miRNA的表达失调,而表观遗传学改变也参与miRNA失调。本文中,我们旨在阐明MYC和miRNA之间的调控网络在前列腺癌发生中的作用。发现在PCa病例和匹配的前体病变中MYC表达上调。 MicroRNA对具有相反MYC水平的PCa样品进行的微阵列分析确定了在高MYC PCa中明显过量表达的miRNA。但是,miR-27a-5p在原发前列腺组织中的验证显示PCa下调,而与异常的启动子甲基化相关。在一系列去势抵抗性PCa(CRPC)病例中,miR-27a-5p连同启动子低甲基化一起被上调。 LNCaP和PC3细胞中的MYC和miR-27a-5p表达水平分别与未使用过激素的PCa和CRPC中观察到的水平相同。 ChIP分析表明,在没有异常启动子甲基化的情况下,miR-27a-5p表达仅受c-Myc调控。 PC3细胞中的MiR-27a-5p敲低促进了细胞生长,而LNCaP中的miRNA强制表达和稳定的MYC敲低的PC3细胞减弱了恶性表型,提示miR-27a-5p具有抑癌作用。此外,miR-27a-5p上调降低了EGFR / Akt1 / mTOR信号传导。我们得出的结论是,miR-27a-5p受MYC的正调控,其异常启动子甲基化导致的沉默在前列腺癌的早期发生,并伴有MYC调控活性的丧失。我们的结果进一步表明,随着PCa的进展,miR-27a-5p启动子被甲基化,从而使MYC恢复其调节活性。但是,改变的细胞环境避免了miR-27a-5p在此疾病阶段成功完成其肿瘤抑制功能。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号